Telisotuzumab adizutecan

DB21832InvestigationalProtein Based Therapies

Telisotuzumab Adizutecan is a biologic drug. Telisotuzumab Adizutecan is under investigation in clinical trial NCT06614192 (A Study Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to...

Mechanism: Pharmacologically active on Hepatocyte growth factor receptor
Curator reviewed
Also known as: Temab-A
Code names: ABBV-400

Resolves to

Compound

UNIICVX52RV2DC

Targets

P08581MET

What you can answer from here — as of May 09, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

19Clinical trialsPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with Telisotuzumab adizutecan, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account